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Background: In order to explore the influence of anxiety on decision–making processes, valid anxiety measures are
needed. We evaluated a prostate cancer screening (PCS) anxiety scale that measures anxiety related to the
prostate–specific antigen (PSA) test, the digital rectal examination (DRE), and the decision to undergo PCS (PCS-D)
using two samples in different settings.
Methods: We assessed four psychometric properties of the scale using baseline data from a randomized, controlled
decision aid trial (n = 301, private clinic; n = 149, public).
Results: The 3-factor measure had adequate internal consistency reliability, construct validity, and discriminant
validity. Confirmatory factor analyses indicated that the 3–factor model did not have adequate fit. When subscales
were considered separately, only the 6–item PCS-D anxiety measure had adequate fit and was invariant across
clinics.
Conclusions: Our results support the use of a 6–item PCS-D anxiety measure with age-appropriate men in public
and private settings. The development of unique anxiety items relating to the PSA test and DRE is still needed.Background
Patient decision aids are recommended for healthcare
decisions for which there is no single best evidence–
based option and personal preferences dictate the best
option [1,2]. Decision aids provide balanced information,
help clarify patient values, and facilitate the weighing the
risks and benefits against a preferred set of personal cri-
teria [1,3]. Whether to receive prostate cancer screening
(PCS) is such a decision in that the best choice relies on
the patient’s preferences for the various risks and bene-
fits [3,4]. Indeed, national organizations that provide
PCS guidelines recommend physicians to discuss the
risks and benefits of screening and treatment and to take
patients’ personal preferences into account [5-9]. Deci-
sion aids are strongly recommended to facilitate PCS
decision-making because several treatments for prostate* Correspondence: SKLinder@mdanderson.org
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reproduction in any medium, provided the orcancer may cause unnecessary physical and psycho-
logical harm [10-14] and because randomized controlled
trials have shown that the prostate–specific antigen
(PSA) test and digital rectal examination (DRE) provide
little or no benefit in the early detection of prostate can-
cer by reducing the prevalence of deaths due to the dis-
ease [11,13].
The influence of affect on cognitive decision–making
processes has been largely ignored in decision aid stud-
ies. Because the affect construct of anxiety is known to
influence effective decision–making, especially in deci-
sions that involve uncertainty [15-17], some researchers
have recommended exploring the moderating role of
anxiety on cognitive decision–making processes [18].
Anxiety may moderate the effect of decision aids as well.
Anxiety is one of the most widely used affect constructs
in decision aid studies but has usually been conceptua-
lized as an outcome rather than a moderator of a deci-
sion [1,19-23].
Researchers have called for decision–specific measures
to be used in decision aid studies [24,25]. Such measures
are necessary because healthcare decisions vary in sociall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Questions from the prostate cancer screening
anxiety measure
PSA anxiety
For having a blood test for cancer. . . Yes No Not Sure
Do you feel tense about the test? [ ] [ ] [ ]
Do you feel upset about the test? [ ] [ ] [ ]
Do you feel nervous about the test? [ ] [ ] [ ]
Do you feel confused about the test? [ ] [ ] [ ]
Do you feel worried about the test? [ ] [ ] [ ]
Do you feel relaxed about the test? [ ] [ ] [ ]
DRE anxiety
For having a test for cancer where the doctor or nurse inserts a
finger into your rectum to perform an exam. . .
Do you feel tense about the exam? [ ] [ ] [ ]
Do you feel upset about the exam? [ ] [ ] [ ]
Do you feel nervous about the exam? [ ] [ ] [ ]
Do you feel confused about the exam? [ ] [ ] [ ]
Do you feel worried about the exam? [ ] [ ] [ ]
Do you feel relaxed about the exam? [ ] [ ] [ ]
PCS-D anxiety
For the decision to be tested for prostate cancer. . .
Do you feel tense about the decision? [ ] [ ] [ ]
Do you feel upset about the decision? [ ] [ ] [ ]
Do you feel nervous about the decision? [ ] [ ] [ ]
Do you feel confused about the decision? [ ] [ ] [ ]
Do you feel worried about the decision? [ ] [ ] [ ]
Do you feel relaxed about the decision? [ ] [ ] [ ]
Note. PCS = prostate cancer screening, PSA = prostate–specific antigen test,
DRE = digital rectal examination.
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place personal importance on the specific decision, the
different types of options, and the uncertainty among
the options, risks, and benefits [26]. Furthermore,
healthcare decisions differ in their potential conse-
quences, in decision needs that must be addressed for
informed decision making to occur, and in timing [27].
In decision aid studies, anxiety is usually conceptualized
as being a general, stable trait instead of anxiety specific-
ally related to aspects of the healthcare decision. For
these reasons, decision–specific anxiety measures are
needed in order to evaluate the role of this affect on cog-
nitive decision–making processes.
In this study, we tested a PCS anxiety scale to deter-
mine the measure’s psychometric properties across to
different samples of age-appropriate men. In order to
generalize and compare the effect of PCS anxiety on
cognitive decision-making processes across different
populations and settings, the measure’s structure must
be invariant. Without measurement invariance, interpre-
tations across samples and settings are not valid. This
secondary analysis used baseline data from a rando-
mized, controlled PCS decision aid trial that had evalu-
ated two decision aids, one at a private clinic and the
other at a public clinic [28]. We assessed the reliability,
construct validity, and discriminant validity for the PCS
anxiety instrument and determined its latent structure
and invariance across settings.
Methods
Development of the PCS anxiety instrument
Two authors (RJV, SKL) originally constructed a 21–
item PCS anxiety measure using wording similar to that
in the Spielberger State–Trait Anxiety Inventory [29].
Three subscales were created using similar wording for
the subscale items. Two subscales related to anxiety
about the screening tests (PSA and DRE subscales), and
the third represented anxiety related to the decision
about undergoing screening for prostate cancer (PCS-D
subscale). For initial determination of content validity
and appropriate word choice, we conducted individual
cognitive interviews with five men each from the public
clinic and the private clinic. As a result of these inter-
views, one item from each proposed subscale was dis-
carded and the statement format was changed to a
question format.
The final PCS anxiety measure consisted of 18 ques-
tions, with 6 items each in three subscales (Table 1).
Each item had ordered categorical response options of
“yes” (4 points), “no” (0 points), and “unsure” (2 points).
One negatively framed item (“relaxed”) in each subscale
was reverse coded. For the overall PCS anxiety score,
the 18 items were summed, divided by the number of
items, and multiplied by 25. The possible range for theoverall value was 0 (no anxiety) through 100 (extremely
high anxiety). The PSA, DRE, and PCS-D anxiety sub-
scale scores were created in a similar fashion.
Participants and procedures
We used de–identified baseline data from a randomized
controlled trial that had compared the effects of a
computerized PCS decision support tool and an active
control tool (audio information booklet) [28]. Between
January 2004 and February 2006, a total of 450 men
had been recruited for the study. These study partici-
pants had been scheduled for non–acute primary care
appointments, had no history of prostate cancer, were
50–70 years of age (40–70 years of age if African–
American), and had not had a PSA test within the previ-
ous 6–12 months. Recruitment occurred at two sites in
Houston, Texas: a general medicine clinic at a publicly
funded hospital (n = 149) and a private, university–
affiliated primary care clinic (n = 301). The following
self–reported variables from the trial were used in our
study: 1) socio–demographic characteristics (i.e., age,
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and family history of prostate cancer), 2) screening
intention, 3) clinic site, and 4) PCS anxiety level. Screen-
ing intention had been indicated by the response to the
question, “Given what you know about prostate cancer
and PSA testing, do you plan to have a PSA test?” with
response options “yes,” “no,” “not sure.” The study sam-
ple characteristics are described elsewhere [28]. Our
study was approved by The University of Texas School
of Public Health Research Service Center and exempted
from review by the Committee for the Protection of
Human Subjects. The original trial had been approved
by the Baylor College of Medicine Institutional Review
Board and the Harris County Hospital District.Data analysis
SPSS version 16.0 was used for descriptive analyses, to
estimate internal consistency reliability, and to estimate
construct and discriminant validity. The chi-square (χ2)
test was used to assess differences in demographic char-
acteristics across clinic sites. Mplus version 5.1 was also
used for internal consistency reliability and for all factor
analyses.Internal consistency reliability
Internal consistency reliability was evaluated using
intraclass correlation coefficients from factor analysis
to account for multiple weights. We expected coeffi-
cients≥ .40. Internal consistency reliability for the over-
all scale and the three subscales for the total sample
and by clinic site is reported using Cronbach’s α,
which we expected to be ≥ .70, the recommended mini-
mum value for acceptable internal consistency reliabil-
ity for research or group comparisons [30].Construct validity
To assess the construct validity of the PCS anxiety in-
strument, we examined patterns of correlations among
the subscales by using a one–tailed Pearson correlation
with p ≤ .05 indicating statistical significance. We
hypothesized that the PCS-D anxiety subscale would be
positively and substantially correlated with the two test-
ing procedure anxiety subscales (DRE and PSA sub-
scales). In other words, if anxiety about the PSA test or
DRE were high, then anxiety about the PCS decision
would also be high. We expected a weaker correlation
between the PSA and DRE anxiety subscales because the
two tests are administered differently (i.e., blood drawn
for testing versus rectal examination). We also expected
men to be more anxious about the DRE than the PSA
test, as would be indicated by higher mean scores for
the DRE anxiety subscale.Discriminant validity
To determine whether the PCS anxiety measure can dif-
ferentiate between groups of men based on screening
intention, the total mean scores of this measure were
compared using two-way analysis of variance (ANOVA)
with p≤ .05 considered statistically significant. The inde-
pendent variables were clinic site and two screening
intention contrasts. The contrasts were created to com-
pare men who had made a decision about undergoing
screening (yes or no) and to compare men who had
made a decision with those who had not (decided versus
unsure). To determine whether the three PCS anxiety
subscales could differentiate groups of men based on
screening intention, a repeated-measures ANOVA was
performed with the mean scores of each subscale
entered as dependent variables. We hypothesized that
men who were undecided would have higher PCS anx-
iety total and subscale scores than men who had made a
decision regarding screening.
Factor validity
Single–group confirmatory factor analyses (CFAs) were
conducted to assess model fit for the proposed 3–factor
model (Figure 1). We used a mean– and variance–
adjusted weighted least squares estimator (WLSMV) be-
cause the data were ordered categorically and the
responses to the anxiety items were non–normally dis-
tributed [31]. This robust estimation of standard errors
and robust χ2 tests of model fit take into account non–
normality of outcomes and non–independence of obser-
vations due to cluster sampling [31].
Model fit was assessed by examining the χ2 test of
model fit, the root mean square error of approximation
(RMSEA), the comparative fit index (CFI), the Tucker–
Lewis index (TLI), and the weighted root mean square
residual (WRMR). A combination of a statistically non–
significant χ2 value (p ≥ .05), RMSEA< .05, CFI and
TLI> .95, and WRMR< .90 indicate adequate model
fit [32,33].
Factor invariance
After finding an acceptable fit based on the single–group
CFA, a two–group CFA was performed to determine
measurement invariance across clinic sites. Two models
were created based on models for measurement invari-
ance of categorical outcomes using WLSM with delta
parameterization: 1) less restrictive: threshold and load-
ing factors free across groups, scale factors fixed at one
in all groups, and factor means fixed at zero in all
groups, and 2) more restrictive: thresholds and factor
loadings constrained to be equal across groups, scale fac-
tors fixed at one in one group and free in others, and
factor means fixed at zero in one group and free in
others [31]. We calculated the χ2 difference between the
Figure 1 Prostate cancer screening anxiety 3–factor model. Note. PCS = prostate cancer screening, PSA = prostate–specific antigen test,
DRE = digital rectal examination.
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DIFFTEST in Mplus [31]. A non–significant χ2 differ-
ence value (p> .05) indicated measurement invariance.Results
Internal consistency reliability
All internal consistency reliability coefficients were ac-
ceptable as indicated by Cronbach’s α≥ .70 (total PCS
anxiety measure, α= .910; PSA anxiety subscale α= .830;
DRE anxiety subscale α= .819; PCS-D anxiety subscale
α= .834). All internal consistency reliability coefficients
were higher for men at the public clinic than at the pri-
vate clinic but not appreciably so (total PCS anxiety
measure α= .927 vs. .895; PSA anxiety subscale α= .837vs. .826; DRE anxiety subscale α= .857 vs. .794; PCS-D
anxiety subscale α= .869 vs. .788). Intraclass correlation
coefficients are not presented because of the lack of fit
found for the 3-factor model.Construct validity
All the three anxiety subscales were positively correlated
and were statistically significant (range, r = .513 – .790, p
< .001 for all comparisons) (Table 2). Following the
same pattern as the internal consistency reliability coeffi-
cients, Pearson correlation coefficients for the anxiety
subscales were higher for men at the public clinic than
those at the private clinic. As we hypothesized, the two
testing procedure subscales were positively correlated
Table 2 Means and correlations coefficients for the prostate cancer screening anxiety
Means (SD) Correlation Coefficients*
Total Public Clinic Private Clinic Total Public Clinic Private Clinic
DRE PCS-D DRE PCS-D DRE PCS-D
PCS anxiety total scale 20.15 (23.43) 23.95 (26.99) 18.25 (21.35) — — — — — —
PSA anxiety subscale 17.62 (26.41) 18.65 (27.61) 17.11 (25.83) .517 .682 .525 .790 .513 .618
DRE anxiety subscale 26.88 (29.85) 30.31 (33.21) 25.28 (27.97) — .642 — .680 — .611
PCS-D anxiety subscale 15.95 (25.27) 22.13 (30.75) 12.84 (21.38) — — — — — —
*All Pearson correlation coefficients were significant at p ≤ 0.01 (1–tailed).
Note. SD =standard deviation, PCS = prostate cancer screening, PSA = prostate–specific antigen test, DRE = digital rectal examination, PCS-D = prostate cancer
screening decision.
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correlated with it than with each other. This finding held
for the total sample as well as for both clinics.
The mean anxiety scores for the total scale and three
subscales were relatively low, ranging from 12.84 to
30.31 out of 100 (Table 2). As we expected, men at both
clinics were more anxious about the DRE than the PSA
test.Discriminant validity
ANOVA results partially supported our hypothesis that
men who were undecided would have higher PCS anx-
iety total and subscale scores than men who had made a
decision regarding screening. The total PCS anxiety
scores can discriminate groups of men based on screen-
ing intention (decided versus unsure) at the public clinic
(Table 3). At the public clinic, men who were unsure
about their screening intention had significantly higher
total PCS anxiety scores (mean = 35.19) than men who
had made a decision about their screening intention
(mean = 20.25). At the private clinic, however, the differ-
ence in total PCS anxiety score was not significant
(decided, mean = 17.94; unsure, mean = 20.25).Table 3 Summary of analysis of variance for clinic site
and screening intention contrasts
Source Sum of Squares df Mean Square F P–Value
Clinic site 443.012 1 443.012 .834 .361
si1 64.799 1 64.799 .122 .727
si2 3,089.853 1 3,089.853 5.820 .016
site * si1 457.553 1 457.553 .862 .354
site * si2 2,687.349 1 2,687.349 5.062 .025
Error 227,220.053 428 530.888
Total 410,817.901 434
Corrected Total 236,416.980 433
Note. df = degrees of freedom; si1 = screening intention (yes versus no); si2 =
screening intention (decided versus undecided); bold font indicates statistical
significance (p < .05).Factor validity
CFAs were conducted separately for each clinic site. The
proposed 3–factor model did not have adequate fit for
either site (Table 4). For the private clinic, inadequate fit
was indicated by the χ2, CFI, RMSEA, and WRMR
values. For the public clinic, inadequate fit was indicated
by the χ2 and RMSEA values.
Exploratory factor analyses were then conducted to
examine factor loadings, which indicated some evidence
for content factors (i.e., PSA, DRE, and PCS-D) and for
method factors. The method factors consisted primarily
of similarly worded items across the subscales. Based on
the factor loadings, a CFA model with 3 content and 6
method factors was completed. Although all indices
indicated adequate model fit for both clinics, over–fit-
ting the model became an issue (9 factors with 18
observed variables). Additionally, two warnings were
given: the residual covariance matrix (theta) and the la-
tent variable covariance matrix (psi) were not positive
definite. These warnings indicated a negative variance/
residual variance for an observed variable and a latent
variable, respectively [31]. When we fixed these var-
iances to 0, the model fit was worse as indicated by the
fit indices and additional warnings resulted for other
items and latent variables. Therefore, we concluded that
the 3–content and 6–method model was not
appropriate.
Three 1–factor CFAs were then completed to separ-
ately analyze anxiety related to the PSA test, DRE, and
PCS-D. For both clinic sites the 1–factor models for
PSA anxiety and PCS-D anxiety fit adequately according
to all fit indices (Table 5). In contrast, the 1–factor
model for DRE anxiety had adequate model fit at the
public clinic, according to all fit indices, but had poor fit
at the private clinic, according to the χ2 and RMSEA
results.
Factor invariance
Finally, to evaluate invariance between the clinics, we
conducted two–group CFAs for a 1–factor PSA anxiety
measure and a 1–factor PCS-D anxiety measure. The χ2
Table 4 Confirmatory factor analyses of the 3–factor prostate cancer screening anxiety model by clinic site
Model Chi–square (df) P–value CFI TLI RMSEA WRMR
Private Clinic
3-Content 178.932 (38) <.001 .921 .960 .112 1.369
3-Content + 6-Method 50.999 (36) .050 .992 .996 .038 .543
Public Clinic
3-Content 71.563 (31) <.001 .967 .985 .095 .884
3-Content + 6-Method 26.565 (29) .595 1.000 1.001 <.001 .420
Note. Content = hypothesized subscales; Method = similarly worded items; CFI = comparative fit index; TLI = Tucker–Lewis index; RMSEA = root mean square error
of approximation; WRMR = weighted root mean square residual; bold font indicates adequate fit.
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measure (p< .0001), and invariance for the second
measure (p = .0889) (Table 6). Comparison of factor
loadings across clinics showed a similar pattern for all
six items. Except for one item (relaxed, reversed coded),
the factor loadings were larger for the private clinic than
for the public clinic. Examination of the categorical item
frequencies revealed some differences in the response
distributions, with men at the public clinic more likely
to use respond “no” (anxious) than men at the private
clinic were, but that most men at both clinics reported
“yes” (not anxious) for all items.Discussion
To our knowledge, this study is the first attempt to as-
sess the factor validity and invariance of an anxiety
measure used in decision aid trials. We used cognitive
interviewing to refine the anxiety items, and we used
factor analyses to evaluate factor validity and invariance.
We also demonstrated the internal consistency reliabil-
ity, the construct validity, and the discriminate validity






CFI TLI RMSEA WRMR
1–Factor PSA anxiety
Private Clinic 6.810 (7) .4489 1.00 1.00 <.001 .379
Public Clinic 7.002 (6) .3207 .999 .999 .034 .382
1–Factor DRE anxiety
Private Clinic 29.662 (7) .0001 .983 .983 .105 .863
Public Clinic 4.334 (7) .7406 1.000 1.004 <.001 .305
1–Factor PCS-D anxiety
Private Clinic 7.154 (6) .3068 .999 .999 .026 .449
Public Clinic 8.776 (7) .2691 .998 .999 .042 .373
Note. df = degrees of freedom; PSA = prostate–specific antigen test,
DRE=digital rectal examination; PCS-D = prostate cancer screening decision;
CFI = comparative fit index; TLI = Tucker–Lewis index; RMSEA = root mean
square error of approximation; WRMR = weighted root mean square residual;
bold font indicates adequate fit.findings from CFA support the use of a 1–factor, 6-item
general anxiety measure for the decision to undergo
PCS as a potential moderator in PCS decision aid studies
that is appropriate to be used in private and public set-
tings. The validity of the PSA and DRE subscales is
uncertain.
Our results also provide partial support for the use of
a 1–factor PSA anxiety measure. Although the measure
was non-invariant across clinics, this result may not be
clinically meaningful in this instance because the factor
loading patterns were similar in direction and only
slightly different in magnitude. Moreover, the small sam-
ple size for the public clinic (n = 149) may have affected
the accuracy and precision of our measurement invari-
ance testing [34]. In addition, the factor loading esti-
mates may be biased due to truncated distributions for
the private clinic sample: categorical item frequencies
indicated that men at the private clinic were less likely
to report “no” (highest anxiety category) than men at the
public clinic. This difference could be due to their his-
tory of PSA testing: men at the private clinic were more
likely to report prior PSA testing than men at the public






CFI TLI RMSEA WRMR
1–Factor PSA anxiety
1. less restrictive 13.052 (13) .4438 1.00 1.00 .004 .560
2. more restrictive 34.804 (12) .0005 .989 .988 .092 1.225
1. vs 2. 23.312 (4) .0001
1–Factor PCS-D anxiety
1. less restrictive 14.206 (12) .2878 .999 .999 .029 .577
2. more restrictive 23.553 (16) .0997 .996 .997 .046 .833
1. vs 2. 9.554 (5) .0889
Note. df = degrees of freedom; PSA = prostate–specific antigen test,
DRE=digital rectal examination; PCS-D = prostate cancer screening decision;
CFI = comparative fit index; TLI = Tucker–Lewis index; RMSEA = root mean
square error of approximation; WRMR = weighted root mean square residual;
bold font indicates adequate fit.
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tion modeling techniques when psychometric properties
of measures are being evaluated. Although our initial
tests for internal consistency reliability and discriminant
and construct validity indicated some evidence for the
3–factor model, factor analyses indicated a high degree
of inter–correlation between items across factors. There
was no evidence of discriminant validity to indicate that
the items were three separate subscales. Many items
loaded on factors other than those proposed, and there
was a high degree of method variance. Some items
seemed to be mostly related to method variance, some
were mostly related to content, and some seemed to
share variance with factors that were not conceptually
identifiable.
The reported low levels of anxiety at both clinics may
also have contributed to the lack of fit for the 3-factor
PCS anxiety measure. Low variability can cause difficulty
in distinguishing between factors. The low anxiety levels
might be due to the prevalence of recent PSA testing.
The low levels could also be due to the nature of the de-
cision: men may not be anxious in general about PCS
because messages about screening are that it is almost
always beneficial [35].
On the basis of our results, we can suggest recommen-
dations for future development of decision-specific
anxiety measures. First, our findings that two of the
three PCS subscales were non-invariant across the two
samples that varied by clinic setting exemplify the im-
portance to evaluate measurement invariance before
comparing scale scores across samples. When measure-
ment non-invariance is found, there may be indication
that the samples differ in their underlying meaning of
the anxiety construct. Therefore, comparisons of the
scores across the samples may not be meaningful. Sec-
ond, developing decision-specific measures may need
more formative work (i.e., cognitive testing or focus
groups) to explore the anxiety specifically related to the
healthcare decision. For PCS, it may be necessary to
understand what makes men anxious about the screening
decision and the testing procedures: some men may be
worried about the type of tests (blood drawn with a nee-
dle or rectal examination), while others may be anxious
about the test results or accuracy. Third, we suggest
avoiding using the same wording across subscales to
minimize method variance. Finally, we recommend not
to include negatively framed items in factor analyses.
During cognitive interviewing, we discarded one nega-
tively framed item (“calm”) that men did not interpret as
the opposite of being anxious However, we included one
negatively framed item (“relaxed”) in each subscale (3
items total) in our PCS anxiety measure. Two of these
three negatively framed items loaded as a separate factor
and not on the respective subscale factor.Our findings have several limitations. First, we did not
measure situational (state) anxiety or underlying (trait)
anxiety. It would be helpful to know how PCS anxiety, a
context–specific anxiety, is different than one’s general
anxiety. Although the comparison groups were based on
clinic site, one serving primarily privately insured
patients and the other primarily publicly insured
patients, there were statistically significant differences
between the men at each clinic (i.e., race/ethnicity, re-
cent history of PSA testing, education, and insurance
status). Our results may not be generalizable to other
private or publicly funded clinics with different patient
compositions. Additionally, given the high percentage of
white men at the private clinic and the high percentage
of black men at the public clinic, the group comparison
results may also be due to differences in race/ethnicity
as well as factors such as insurance status. Future valid-
ity testing should explore differences in race/ethnicity
with populations of the same insurance and socio-
economic status. Finally, we used a well validated anxiety
measure as a starting point to develop anxiety items spe-
cific for prostate cancer screening and used cognitive
testing to verify the initial content validity of the items.
To develop unique items related to aspects about the
healthcare decision, other qualitative methods like using
focus groups to find out what people find anxious about
healthcare decisions may provide a better insight for
content domain and to generate a pool of items.
Conclusions
Our six–item PCS-D anxiety measure could be used as a
moderator in PCS decision aid studies. Our six–item
PSA anxiety measure may also be used in PCS decision
aid studies, although further invariance testing is needed
to ensure accurate interpretation across populations that
differ in race/ethnicity, level of education, and history of
PSA testing, as well as insurance status. These two anx-
iety measures should be tested with other samples of
men eligible for PCS. These anxiety measures are
intended for research purposes and should not be used
as a clinical diagnostic tool for anxiety. To develop a
PCS anxiety measure with subscales related to the
screening tests as well as the decision to undergo
screening, researchers might use other qualitative tech-
niques to generate an item pool of items. To minimize
method variance, we recommend avoiding the use of
similar wording across subscales.
Future research in decision aid studies should report
the evidence for the validity of the factor structure
and the invariance for affect measures. Because anxiety
can influence effective decision–making and therefore
modify the effects of decision aids, valid and reliable
healthcare–specific anxiety measures are needed for
other healthcare decisions other than PCS that involve
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ence of anxiety on cognitive decision–making processes
and differences across can be explored.
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